1-20 of 204
Ghayas C. Issa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Available to Purchase
Sven Turkalj, Felix A. Radtke, Bilyana Stoilova, Rabea Mecklenbrauck, Angus J. Groom, Niels Asger Jakobsen, Curtis A. Lachowiez, Marlen Metzner, Batchimeg Usukhbayar, Mirian Angulo Salazar, Zhihong Zeng, Sanam Loghavi, Jennifer Marvin-Peek, Verena Körber, Farhad Ravandi, Ghayas C. Issa, Tapan M. Kadia, Vasiliki Symeonidou, Anne P. de Groot, Hagop M Kantarjian, Koichi Takahashi, Marina Konopleva, Courtney D. DiNardo, Paresh Vyas
Journal: Blood
Blood blood.2024027948.
https://doi.org/10.1182/blood.2024027948
Published: 2025
Includes: Supplemental data
Journal Articles

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Available to Purchase
Reeja Raj, Samanta Catueno, Amber Gibson, David McCall, Miriam B. Garcia, Cesar Nunez, Michael E. Roth, Koji Sasaki, Priti Tewari, Ghayas C. Issa, Aziz Farhat, Jeremy S Connors, Irtiza Naseer Sheikh, Yuki Nishida, Joanna S Yi, Alexandra M Stevens, Alex Bataller, Kapil N Bhalla, Demetrios Petropoulos, Naval G Daver, Tapan M. Kadia, Branko Cuglievan, Courtney D. DiNardo
Journal: Blood
Blood blood.2025029391.
https://doi.org/10.1182/blood.2025029391
Published: 2025
Includes: Supplemental data
Journal Articles

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Open Access
Clinical Trials & Observations
Martha L. Arellano, Michael J. Thirman, John F. DiPersio, Maël Heiblig, Eytan M. Stein, Andre C. Schuh, Andrius Žučenka, Stephane de Botton, Carolyn S. Grove, Gabriel N. Mannis, Cristina Papayannidis, Alexander E. Perl, Ghayas C. Issa, Ibrahim Aldoss, Ashish Bajel, David S. Dickens, Michael W. M. Kühn, Ioannis Mantzaris, Emmanuel Raffoux, Elie Traer, Irina Amitai, Hartmut Döhner, Corinna Greco, Tibor Kovacsovics, Christine M. McMahon, Pau Montesinos, Arnaud Pigneux, Paul J. Shami, Richard M. Stone, Ofir Wolach, John G. Harpel, Yakov Chudnovsky, Li Yu, Rebecca G. Bagley, Angela R. Smith, James S. Blachly
Journal: Blood
Blood (2025) 146 (9): 1065–1077.
https://doi.org/10.1182/blood.2025028357
Published: 2025
Includes: Supplemental data
Journal Articles

How I treat acute myeloid leukemia with differentiation therapy

Available to Purchase
Ghayas C. Issa, Eytan M. Stein, Courtney D. DiNardo
Journal: Blood
Blood (2025) 145 (12): 1251–1259.
https://doi.org/10.1182/blood.2024024008
Published: 2025
Journal Articles

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Free
Sankalp Arora, Musa Yilmaz, Wei-Ying Jen, Nicholas J. Short, Sanam Loghavi, Tapan M. Kadia, Courtney D. DiNardo, Gautam Borthakur, Indraneel Deshmukh, Ghayas C. Issa, Joseph E. Jabbour, Naveen Pemmaraju, Michael Andreeff, Koichi Takahashi, Kapil N. Bhalla, Hussein A. Abbas, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Naval Daver
Journal: Blood
Blood (2024) 144 (Supplement 1): 841.
https://doi.org/10.1182/blood-2024-204042
Published: 2024
Journal Articles

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Free
Amer M. Zeidan, Eunice S. Wang, Ghayas C. Issa, Harry Erba, Jessica Kaplan Altman, Suresh Kumar Balasubramanian, Stephen Anthony Strickland, Gail J. Roboz, Gary J. Schiller, Christine M. McMahon, Neil D. Palmisiano, Yazan F. Madanat, Marcello Rotta, Kalyan Nadiminti, Helen Wei, Marcie Riches, Daniel Corum, Mollie Leoni, Stephen Dale, Amir T. Fathi
Journal: Blood
Blood (2024) 144 (Supplement 1): 214.
https://doi.org/10.1182/blood-2024-198218
Published: 2024
Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Free
Ibrahim Aldoss, Ghayas C. Issa, James S. Blachly, Michael J. Thirman, Gabriel N Mannis, Martha L. Arellano, John F. DiPersio, Elie Traer, C. Michel Zwaan, Neerav Shukla, Branko Cuglievan, Carolyn S. Grove, Matthew Greenwood, Christine M. McMahon, Alexander E. Perl, Richard M. Stone, Cristina Papayannidis, David S. Dickens, Maël Heiblig, Andrius Žučenka, Pau Montesinos, Ioannis Mantzaris, Tibor Kovacsovics, Paul J. Shami, Li Yu, Rebecca G. Bagley, Nicole McNeer, Eytan M. Stein
Journal: Blood
Blood (2024) 144 (Supplement 1): 211.
https://doi.org/10.1182/blood-2024-194384
Published: 2024
Journal Articles

Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

Free
Alex Bataller, Hagop M. Kantarjian, Alexandre Bazinet, Jayastu Senapati, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2024) 144 (Supplement 1): 56.
https://doi.org/10.1182/blood-2024-202620
Published: 2024
Journal Articles

Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

Free
Edward Ayoub, David Lehotzky, Li Li, Muharrem Muftuoglu, Yuki Nishida, Vakul Mohanty, Jake S Leighton, Tallie Patsilevas, Mahesh Basyal, Andrea Bedoy, Torsten Haferlach, Koichi Takahashi, Ken Chen, Nicholas Navin, Ghayas C. Issa, Gad Getz, Michael Andreeff
Journal: Blood
Blood (2024) 144 (Supplement 1): 61.
https://doi.org/10.1182/blood-2024-211845
Published: 2024
Journal Articles

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Free
Courtney D. DiNardo, Kelly S. Chien, Jillian Mullin, Danielle Hammond, Jeremy Ramdial, Tapan M. Kadia, Fadi G. Haddad, Musa Yilmaz, Koji Sasaki, Ghayas C. Issa, Koichi Takahashi, Elizabeth J. Shpall, Farhad Ravandi, Naval Daver, Hagop Kantarjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 1527.2.
https://doi.org/10.1182/blood-2024-208771
Published: 2024
Journal Articles

A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Trial in Progress

Free
Nicholas J. Short, Farhad Ravandi, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Musa Yilmaz, Ghayas C. Issa, Regina Abramova, Araceli Isabella Garza, Hagop M. Kantarjian, Hussein A. Abbas
Journal: Blood
Blood (2024) 144 (Supplement 1): 4288.1.
https://doi.org/10.1182/blood-2024-200923
Published: 2024
Journal Articles

A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia

Free
Hannah Goulart, Hagop M. Kantarjian, Naval Daver, Musa Yilmaz, Guillermo Garcia-Manero, Kelly S. Chien, Jan A. Burger, Naveen Pemmaraju, Courtney D. DiNardo, Nicholas J. Short, Guillermo Montalban-Bravo, Abhishek Maiti, Danielle Hammond, Ghayas C. Issa, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2024) 144 (Supplement 1): 2901.
https://doi.org/10.1182/blood-2024-205340
Published: 2024
Journal Articles

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Free
Alexandre Bazinet, Guillermo Garcia-Manero, Alex Bataller, Yesid Alvarado Valero, Musa Yilmaz, Elias Jabbour, Guillermo Montalban-Bravo, Naveen Pemmaraju, Ghayas C. Issa, Nicholas J. Short, Tapan M. Kadia, Nitin Jain, Lucia Masarova, Naval Daver, Danielle Hammond, Gautam Borthakur, Abhishek Maiti, Koichi Takahashi, Kelly S. Chien, Steven M. Kornblau, Hussein A. Abbas, Maro Ohanian, Jayastu Senapati, Courtney D. DiNardo, Hagop M. Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2024) 144 (Supplement 1): 2896.
https://doi.org/10.1182/blood-2024-198541
Published: 2024
Journal Articles

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Free
Jennifer Marvin-Peek, Himachandana Atluri, Nicholas J. Short, Abhishek Maiti, Koichi Takahashi, Sanam Loghavi, Curtis A Lachowiez, Yesid Alvarado Valero, Guillermo Montalban-Bravo, Koji Sasaki, Fadi G. Haddad, Ghayas C. Issa, Lucia Masarova, Hussein A. Abbas, Michael Andreeff, Gautam Borthakur, Jillian Mullin, George Donovan Tippett, Kelly S. Chien, Danielle Hammond, Jo Ishizawa, Nitin Jain, Patrick K. Reville, Mahesh Swaminathan, Musa Yilmaz, Naval Daver, Tapan M. Kadia, Farhad Ravandi, Guillermo Garcia-Manero, Hagop M. Kantarjian, Courtney D. DiNardo
Journal: Blood
Blood (2024) 144 (Supplement 1): 2883.
https://doi.org/10.1182/blood-2024-200387
Published: 2024
Journal Articles

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Free
Amir T. Fathi, Ghayas C. Issa, Eunice S. Wang, Harry Erba, Jessica Kaplan Altman, Suresh Kumar Balasubramanian, Gail J. Roboz, Gary J. Schiller, Christine M. McMahon, Neil D. Palmisiano, Mark B Juckett, Yazan F. Madanat, Marcello Rotta, Keith W. Pratz, George Yaghmour, Kalyan Nadiminti, Helen Wei, Marcie Riches, Daniel Corum, Mollie Leoni, Stephen Dale, Amer M. Zeidan
Journal: Blood
Blood (2024) 144 (Supplement 1): 2880.
https://doi.org/10.1182/blood-2024-199170
Published: 2024
Journal Articles

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Free
Sanam Loghavi, Sa A. Wang, Wei-Ying Jen, Wei Wang, Hong Fang, Shaoying Li, Sofia A. Garces, Andres E Quesada, Jie Xu, Chi Young Ok, Shimin Hu, Jeffrey L. Jorgensen, Guilin Tang, Cedric Nasnas, Omer Karrar, Ghayas C. Issa, Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Hagop M. Kantarjian, L. Jeffrey Medeiros, Farhad Ravandi, Nicholas J. Short
Journal: Blood
Blood (2024) 144 (Supplement 1): 4336.
https://doi.org/10.1182/blood-2024-209462
Published: 2024
Journal Articles

CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia

Free
Susan Y. Wu, Koji Sasaki, Penny Q. Fang, Nicholas J. Short, Jillian R. Gunther, Wenli Dong, Ethan P. Damron, Lewis F. Nasr, David R. Boyce, Abhishek Maiti, Chelsea C. Pinnix, Ghayas C. Issa, Nitin Jain, Courtney D. DiNardo, Farhad Ravandi, Elias Jabbour, Partow Kebriaei, Bouthaina S. Dabaja
Journal: Blood
Blood (2024) 144 (Supplement 1): 4182.
https://doi.org/10.1182/blood-2024-209393
Published: 2024
Journal Articles

Early Predictors of Treatment-Free Remission in Chronic Myeloid Leukemia

Free
Aziz Farhat, Hagop M. Kantarjian, Fadi G. Haddad, Nicholas J. Short, Guillermo Montalban-Bravo, Danielle Hammond, Elias Jabbour, Guillermo Garcia-Manero, Koji Sasaki, Ghayas C. Issa
Journal: Blood
Blood (2024) 144 (Supplement 1): 6605.
https://doi.org/10.1182/blood-2024-208569
Published: 2024
Journal Articles

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Free
Ghayas C. Issa, Alexander J. Ambinder, Wenbin Xiao, Scott Manalis, Alex K Shalek, Lukasz P. Gondek, Alex Kentsis, Nicholas J. Short, Naval Daver, Jing Ning, Lianchun Xiao, Michael Hemann, Ken Chen, Keyur P. Patel, Pavan Bachireddy, Andrew A. Lane, Marina Konopleva, Omar Abdel-Wahab, Jeffrey J. Molldrem, Ross L Levine, Mark J. Levis, Richard M Stone, Michael Andreeff, Farhad Ravandi, Aaron D. Goldberg, Jacqueline S. Garcia
Journal: Blood
Blood (2024) 144 (Supplement 1): 4265.2.
https://doi.org/10.1182/blood-2024-201582
Published: 2024
Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Free
Mahesh Swaminathan, Philip A. Thompson, Jan A. Burger, Musa Yilmaz, Nitin Jain, Tapan M. Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Alessandra Ferrajoli, Ghayas C. Issa, Steven M. Kornblau, Farhad Ravandi, Koji Sasaki, Gautam Borthakur, Kelly S. Chien, Courtney D. DiNardo, Danielle Hammond, Elias Jabbour, Guillermo Montalban-Bravo, Naveen Pemmaraju, Nicholas J. Short, Koichi Takahashi, Francesco Paolo Tambaro, Wei Qiao, Naveen Garg, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 1855.
https://doi.org/10.1182/blood-2024-211110
Published: 2024